- Home
- QLYS vs EWTX Comparison
QLYS vs EWTX Comparison
Compare QLYS & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QLYS | EWTX |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QLYS | EWTX |
|---|---|---|
| Price | $88.12 | $33.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $136.00 | $37.38 |
| AVG Volume (30 Days) | 543.4K | ★ 797.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.99 | N/A |
| EPS | ★ 5.44 | N/A |
| Revenue | ★ $321,607,000.00 | N/A |
| Revenue This Year | $9.96 | N/A |
| Revenue Next Year | $7.15 | N/A |
| P/E Ratio | $16.25 | ★ N/A |
| Revenue Growth | ★ 15.32 | N/A |
| 52 Week Low | $82.06 | $10.60 |
| 52 Week High | $155.47 | $33.56 |
Technical Indicators
Market Signals| Indicator | QLYS | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.17 | 64.14 |
| Support Level | $85.14 | $28.72 |
| Resistance Level | $102.25 | N/A |
| Average True Range (ATR) | 4.34 | 1.43 |
| MACD | -0.01 | 0.27 |
| Stochastic Oscillator | 35.12 | 95.20 |
Price Performance
Historical ComparisonAbout QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.